Staidson (Beijing) Biopharmaceuticals Co., Ltd
27
4
4
18
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.5%
5 terminated/withdrawn out of 27 trials
78.3%
-8.2% vs industry average
7%
2 trials in Phase 3/4
0%
0 of 18 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
A Study to Evaluate the Safety and Tolerability of Single and Multiple Dose of STSP-0902 in Healthy Subjects
Role: lead
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Role: lead
A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects
Role: lead
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
Role: lead
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
Role: lead
To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
Role: lead
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
Role: lead
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects
Role: lead
Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
Role: lead
A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
Role: lead
A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
Role: lead
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
Role: lead
A Study of STSA-1201 in Healthy Subjects
Role: lead
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
Role: lead
A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects
Role: lead
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients
Role: lead
Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Role: lead
Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor
Role: lead
The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects
Role: lead
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
Role: lead